Ош мамлекеттик университетинин Жарчысы. Медицина
Ош мамлекеттик университетинин Жарчысы. Медицина
e-ISSN 1694-8831
DOI: 10.52754/16948831
Макала тапшыруу

Макала

Макаланы жүктөө

Коморбиддик оорулары бар Covid-19 үчүн адистештирилген медициналык жардам көрсөтүү системасы

Назгуль Омурзакова, Рыскүл Кыдыралиева, Акпай Сарыбаев

Кабыл алынган убакыт 10.06.2025, Түзөтүлгөн 04.11.2025, Кабыл алынган 17.12.2025

Аннотация

Изилдөөнүн максаты коронавирустук инфекция жана өнөкөт оорулары бар бейтаптарга адистештирилген жардамды уюштуруунун өзгөчөлүктөрүн изилдөө жана анын натыйжалуулугун жана жакшыртуу мүмкүнчүлүктөрүн андан ары баалоо болгон. Изилдөө теориялык жана аналитикалык мүнөздө болуп, алты кластерди салыштырууну камтыды: Кыргызстан ресурстары чектелген өлкөнүн үлгүсү катары, Америка Кошмо Штаттары, Европа өлкөлөрү (Франция, Германия, Италия, Испания, Польша), Азия өлкөлөрү (Таиланд, Сингапур, Индонезия, Түштүк Корея, Индия, Малайзия), ошондой эле борборлоштурулган уюм менен Кытай жана Япония. Талдоо 2020-2025-жылдарга жарыяланган басылмаларга, статистикага жана клиникалык көрсөтмөлөргө негизделген; Өлкөлөр аралык салыштыруу коштолгон оорулуулардын оордугуна шарттуу баллдык баа берүү жана жардам көрсөтүүнү жакшыртуу боюнча сунуштарды иштеп чыгуу менен колдонулган. Талдоо көрсөткөндөй, көп оорулуулар менен оордуктун индекси 16 баллга жеткен, ал эми жүрөк-кан тамыр, респиратордук оорулар жана иммундук жетишсиздик менен – 15. Эки же андан көп өнөкөт патологиялар оор агымдын жана өлүмдүн коркунучун 2-3 эсеге жогорулаткан. Кытайда жана Японияда ооруканадагы өлүм 5,5-6 % түздү, Японияда бөйрөктүн оор жетишсиздиги менен – 28 % га чейин. Америка Кошмо Штаттарында бир нече өнөкөт оорулары менен ооругандардын өлүмү 12 % дан ашты, жалпысынан 2,5 %, тез жардам бөлүмдөрүндөгү жүк 25-30 % га жетти. Европада эң жогорку мезгилдерде өлүмдүн өсүшү болжол менен 20 % ды түздү, ресурстардын жетишсиздиги менен – 50-60 % га чейин, Италияда жана Испанияда рак менен ооругандардын арасында – 25 % дан ашык. Кыргызстанда кургак учуктун көп дары-дармектерге туруктуулугу менен бул көрсөткүч 34-36 % га жетти. Алынган маалыматтар тобокелдикти стратификациялоону, протоколдорду адаптациялоону жана адам ресурстарын жана инфраструктуралык потенциалды чыңдоону талап кылган кошумча оорулардын оордугунан жана саламаттык сактоо ресурстарынан көз карандылыгын тастыктайт. Натыйжалар саламаттыкты сактоо органдары жана медициналык мекемелер тарабынан коронавирус инфекциясы жана өнөкөт оорулары бар бейтаптарга жардам көрсөтүүнү оптималдаштыруу үчүн колдонсо болот


Негизги сөздөр:

ооруканага жаткыруу; өлүм; багыттоо; тобокелдик стратификациясы; кычкылтек терапиясы; телемедицина; көп тармактуу команда

https://doi.org/10.52754/16948645_2025_4(2)_08

Алуу булагы Том 4, № 2, 2025

Барактар 8-23

Колдонулган булактар Цитаталоо

Колдонулган булактар

  1. World Health Organisation. COVID-19 epidemiological update. 177 ed. Geneva: World Health Organization; 2025. 31 P.
  2. Asai Y, Ohashi T, Imai K, Murata K, Tsuzuki S, Matsunaga N, et al. Differences in COVID-19 treatment across Japan: Analysis of the COVID‑19 Registry Japan (COVIREGI‑JP). J Inf Chemother. 2024;30(1):20–8. DOI: 10.1016/j.jiac.2023.09.005
  3. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with COVID 19 in China: A nationwide analysis. Eur Respir J. 2020;55(5):2000547. DOI: 10.1183/13993003.00547-2020
  4. Zhang Q. Introducing the new versions of Chinese diagnosis and treatment protocol for COVID-19. Infect Microbes Dis. 2022;4(3):83–4. DOI: 10.1097/IM9.0000000000000099
  5. Russell CD, Lone NI, Baillie JK. Comorbidities, multimorbidity and COVID-19. Nat Med. 2023;29(2):334–43. DOI: 10.1038/s41591-022-02156-9
  6. Kendzerska T, Zhu DT, Gershon AS, Edwards JD, Peixoto C, Robillard R, et al. The effects of the health system response to the COVID-19 pandemic on chronic disease management: A narrative review. Risk Manag Healthc Policy. 2021;14:575–84. DOI: 10.2147/RMHP.S293471
  7. Fitero A, Bungau SG, Tit DM, Endres L, Khan SA, Bungau AF, et al. Comorbidities, associated diseases, and risk assessment in COVID-19 – a systematic review. Int J Clin Pract. 2022;2022:1571826. DOI: 10.1155/2022/1571826
  8. Fekadu G, Bekele F, Tolossa T, Fetensa G, Turi E, Getachew M, et al. Impact of COVID-19 pandemic on chronic diseases care follow-up and current perspectives in low resource settings: A narrative review. Int J Physiol Pathophysiol Pharmacol. 2021;13(3):86–93.
  9. Akmatova R, Otorbaeva D, Ebama MS. Impact of the COVID 19 pandemic on influenza knowledge, attitudes, and vaccination practices in at risk groups in the Kyrgyz Republic: A comparative study. Vaccine. 2025;56:127159. DOI: 10.1016/j.vaccine.2025.127159
  10. Rechel B, Moldoisaeva S, Shriwise A. Health systems in action: Kyrgyzstan. Copenhagen: European Observatory on Health Systems and Policies; World Health Organization; 2022. 24 P.
  11. Taalaibekova A, Oleinik A, Magdieva K, Mirzalieva G, Yusuf ZK, Yusuf Z, et al. Views of healthcare workers on development of support for people with post-COVID syndrome in Kyrgyzstan: A survey study. Glob Health Res. 2024. DOI: 10.3310/DGWW4396
  12. Underlying conditions and the higher risk for severe COVID‑19 [Internet]. [cited 2025 September 8]. Available from: https://www.cdc.gov/covid/hcp/clinical-care/underlying-conditions.html
  13. Zaikov SV. COVID 19 and comorbid chronic diseases. Infus Chemother. 2020;3(3):5–10. DOI: 10.32902/2663-0338-2020-3-5-10
  14. Jakhmola S, Indari O, Baral B, Kashyap D, Varshney N, Das A, et al. Comorbidity assessment is essential during COVID-19 treatment. Front Physiol. 2020;11:984. DOI: 10.3389/fphys.2020.00984
  15. World Health Organization. WHO Coronavirus (COVID-19) dashboard [Internet]. [cited 2025 September 8]. Available from: https://data.who.int/dashboards/covid19/cases
  16. World Bank. COVID-19 High-Frequency Monitoring Dashboard [Internet]. [cited 2025 September 8]. Available from: https://www.worldbank.org/en/data/interactive/2020/11/11/covid-19-high-frequency-monitoring-dashboard
  17. European Centre for Disease Prevention and Control. COVID‑19 Situation Updates and Surveillance Reports [Internet]. [cited 2025 September 8]. Available from: https://www.ecdc.europa.eu/en/covid-19
  18. Centres for Disease Control and Prevention. COVID‑19 data tracker [Internet]. [cited 2025 September 8]. Available from: https://covid.cdc.gov/covid-data-tracker/#datatracker-home
  19. Ministry of Health, Labour and Welfare of Japan. Novel Coronavirus (COVID‑19) [Internet]. [cited 2025 September 8]. Available from: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000164708_00079.html
  20. National Health Commission of the People’s Republic of China. Diagnosis and treatment protocol for COVID‑19 patients. 8th ed. Beijing: National Health Commission of the People’s Republic of China; 2020. 31 P.
  21. National Institute for Health and Care Excellence. COVID‑19 rapid guideline: Managing COVID‑19 [Internet]. [cited 2025 September 8]. Available from: https://www.nice.org.uk/guidance/ng191
  22. Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med. 2020;2(8):1069–76. DOI: 10.1007/s42399-020-00363-4
  23. Elezkurtaj S, Greuel S, Ihlow J, Michaelis EG, Bischoff P, Kunze CA, et al. Causes of death and comorbidities in hospitalized patients with COVID-19. Sci Rep. 2021;11(1):4263. DOI: 10.1038/s41598-021-82862-5
  24. Barh D, Aljabali AA, Tambuwala MM, Tiwari S, Serrano-Aroca Á, Alzahrani KJ, et al. Predicting COVID-19 – comorbidity pathway crosstalk-based targets and drugs: Towards personalized COVID-19 management. Biomedicines. 2021;9(5):556. DOI: 10.3390/biomedicines9050556
  25. Biswas M, Rahaman S, Biswas TK, Haque Z, Ibrahim B. Association of sex, age, and comorbidities with mortality in COVID-19 patients: A systematic review and meta-analysis. Intervirology. 2021;64(1):36–47. DOI: 10.1159/000512592
  26. Das S, Grant L, Fernandes G. Task shifting healthcare services in the post-COVID world: A scoping review. PLOS Glob Public Health. 2023;3(12):e0001712. DOI: 10.1371/journal.pgph.0001712
  27. Alumkulova G, Hazoyan A, Zhdanova E, Kuznetsova Y, Tripathy JP, Sargsyan A, et al. Discharge outcomes of severely sick patients hospitalized with multidrug-resistant tuberculosis, comorbidities, and serious adverse events in Kyrgyz Republic, 2020-2022. Trop Med Infect Dis. 2023;8(7):338. DOI: 10.3390/tropicalmed8070338
  28. Xu S, Glenn S, Sy L, Qian L, Hong V, Ryan DS, et al. Impact of the COVID-19 pandemic on health care utilization in a large integrated health care system: Retrospective cohort study. J Med Internet Res. 2021;23(4):e26558. DOI: 10.2196/26558
  29. Kwok CS, Muntean EA, Mallen CD. The impact of COVID-19 on the patient, clinician, healthcare services and society: A patient pathway review. J Med Virol. 2022;94(8):3634–41. DOI: 10.1002/jmv.27758
  30. Grimm CA. Hospitals reported that the COVID-19 pandemic has significantly strained health care delivery. Washington: U.S. Department of Health and Human Services; 2021. 62 P.
  31. Khera A, Baum SJ, Gluckman TJ, Gulati M, Martin SS, Michos ED, et al. Continuity of care and outpatient management for patients with and at high risk for cardiovascular disease during the COVID-19 pandemic: A scientific statement from the American society for preventive cardiology. Am J Prev Cardiol. 2020;1:100009. DOI: 10.1016/j.ajpc.2020.100009
  32. Schieber LZ, Dunphy C, Schieber RA, Lopes-Cardozo B, Moonesinghe R, Guy GP. Hospitalization associated with comorbid psychiatric and substance use disorders among adults with COVID-19 treated in US emergency departments from April 2020 to August 2021. JAMA Psychiatry. 2023;80(4):331–41. DOI: 10.1001/jamapsychiatry.2022.5047
  33. Tuczyńska M, Staszewski R, Matthews-Kozanecka M, Żok A, Baum E. Quality of the healthcare services during COVID-19 pandemic in selected European countries. Front Public Health. 2022;10:870314. DOI: 10.3389/fpubh.2022.870314
  34. Semenzato L, Botton J, Drouin J, Cuenot F, Dray-Spira R, Weill A, et al. Chronic diseases, health conditions and risk of COVID-19-related hospitalization and in-hospital mortality during the first wave of the epidemic in France: A cohort study of 66 million people. Lancet Reg Health Eur. 2021;8:100158. DOI: 10.1016/j.lanepe.2021.100158
  35. Lupu D, Tiganasu R. COVID-19 and the efficiency of health systems in Europe. Health Econ Rev. 2022;12(1):14. DOI: 10.1186/s13561-022-00358-y
  36. Noknoy S, Kassai R, Sharma N, Nicodemus L, Canhota C, Goodyear-Smith F. Integrating public health and primary care: The response of six Asia-Pacific countries to the COVID-19 pandemic. Br J Gen Pract. 2021;71(708):326–9. DOI: 10.3399/bjgp21X716417
  37. Master R, Rana N, Chang L, Ponniah J, Duong DB. The Asia Pacific experience of primary health care in the COVID-19 pandemic. In: Basu S, Alpert JL, Phillips RS, editors. Primary care in the COVID-19 pandemic. Boston (MA): Harvard Medical School Center for Primary Care; 2020. P. 53–67.
  38. Gadsden T, Downey LE, Vilas VDR, Peiris D, Jan S. The impact of COVID-19 on essential health service provision for noncommunicable diseases in the South-East Asia region: A systematic review. Lancet Reg Health Southeast Asia. 2022;1:100010. DOI: 10.1016/j.lansea.2022.04.006
  39. Mishra A, Basumallick S, Lu A, Chiu H, Shah MA, Shukla Y, et al. The healthier healthcare management models for COVID-19. J Infect Public Health. 2021;14(7):927–37. DOI: 10.1016/j.jiph.2021.05.014
  40. Terada M, Ohtsu H, Saito S, Hayakawa K, Tsuzuki S, Asai Y, et al. Risk factors for severity on admission and the disease progression during hospitalization in a large cohort of COVID-19 patients in Japan. BMJ Open. 2021;11:e047007. DOI: 10.1101/2021.04.02.21254809
  41. Pasello G, Menis J, Pilotto S, Frega S, Belluomini L, Pezzuto F, et al. How the COVID-19 pandemic impacted on integrated care pathways for lung cancer: The parallel experience of a COVID-spared and a COVID-dedicated center. Front Oncol. 2021;11:669786. DOI: 10.3389/fonc.2021.669786
  42. Loungani RS, Rehorn MR, Newby LK, Katz JN, Klem I, Mentz RJ, et al. A care pathway for the cardiovascular complications of COVID-19: Insights from an institutional response. Am Heart J. 2020;225:3–9. DOI: 10.1016/j.ahj.2020.04.024
  43. Adab P, Haroon S, O’Hara ME, Jordan RE. Comorbidities and COVID-19. BMJ. 2022;377:o1431. DOI: 10.1136/bmj.o1431
  44. Chang AY, Cullen MR, Harrington RA, Barry M. The impact of novel coronavirus COVID-19 on noncommunicable disease patients and health systems: A review. J Intern Med. 2021;289(4):450–62. DOI: 10.1111/joim.13184
  45. Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, et al. COVID-19 and comorbidities: Deleterious impact on infected patients. J Infect Public Health. 2020;13(12):1833–9. DOI: 10.1016/j.jiph.2020.07.014
  46. Ashmawy R, Hammouda EA, El-Maradny YA, Aboelsaad I, Hussein M, Uversky VN, et al. Interplay between comorbidities and long COVID: Challenges and multidisciplinary approaches. Biomolecules. 2024;14(7):835. DOI: 10.3390/biom14070835
  47. Katz GM, Bach K, Bobos P, Cheung A, Décary S, Goulding S, et al. Understanding how post-COVID-19 condition affects adults and health care systems. JAMA Health Forum. 2023;4(7):e231933. DOI: 10.1001/jamahealthforum.2023.1933
  48. Kuryata OV, Semenov VV, Fetkhi S, Frolova YO. Comorbidity and extra pulmonary manifestations in hospitalized patients with coronavirus disease (COVID-19) depending on age and sex. Med Perspekt. 2024;29(1):74–82. DOI: 10.26641/2307-0404.2024.1.300503
  49. Mahuela L, Oliván-Blázquez B, Lear-Claveras A, Méndez-López F, Samper-Pardo M, León-Herrera S, et al. Use of health services and medication use, new comorbidities, and mortality in patients with chronic diseases who did not contract COVID-19 during the first year of the pandemic: A retrospective study and comparison by sex. BMC Health Serv Res. 2023;23(1):1364. DOI: 10.1186/s12913-023-10158-7
  50. Tartof SY, Qian L, Hong V, Wei R, Nadjafi RF, Fischer H, et al. Obesity and mortality among patients diagnosed with COVID-19: Results from an integrated health care organization. Ann Intern Med. 2020;173(10):773–81. DOI: 10.7326/M20-3742
  51. Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol. 2020;75(18):2352–71. DOI: 10.1016/j.jacc.2020.03.031
  52. Huang BZ, Creekmur B, Yoo MS, Broder B, Subject C, Sharp AL. Healthcare utilization among patients diagnosed with COVID-19 in a large integrated health system. J Gen Intern Med. 2022;37(4):830–7. DOI: 10.1007/s11606-021-07139-z
  53. Skyrud KD, Hernæs KH, Telle KE, Magnusson K. Impacts of mild COVID-19 on elevated use of primary and specialist health care services: A nationwide register study from Norway. PLoS One. 2021;16(10):e0257926. DOI: 10.1371/journal.pone.0257926
  54. Zhou Y, Chi J, Lv W, Wang Y. Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (COVID-19). Diabetes Metab Res Rev. 2021;37(2):e3377. DOI: 10.1002/dmrr.3377
  55. Al-Quteimat OM, Amer AM. The impact of the COVID-19 pandemic on cancer patients. Am J Clin Oncol. 2020;43(6):452–5. DOI: 10.1097/COC.0000000000000712
  56. Bakouny Z, Hawley JE, Choueiri TK, Peters S, Rini BI, Warner JL, et al. COVID-19 and cancer: Current challenges and perspectives. Cancer Cell. 2020;38(5):629–46. DOI: 10.1016/j.ccell.2020.09.018
  57. Ssentongo P, Heilbrunn ES, Ssentongo AE, Advani S, Chinchilli VM, Nunez JJ, et al. Epidemiology and outcomes of COVID-19 in HIV-infected individuals: A systematic review and meta-analysis. Sci Rep. 2021;11(1):6283. DOI: 10.1038/s41598-021-85359-3
  58. Cooper TJ, Woodward BL, Alom S, Harky A. Coronavirus disease 2019 (COVID-19) outcomes in HIV/AIDS patients: A systematic review. HIV Med. 2020;21(9):567–77. DOI: 10.1111/hiv.12911

Цитаталоо

APA
Omurzakova, N., Kydyralieva, R., & Sarybaev, A. (2025). System for the provision of specialised medical care for Covid-19 with comorbid diseases. Journal of Osh State University. Medicine, 4(2), 8-23. https://doi.org/10.52754/16948645_2025_4(2)_08
Vancouver
Omurzakova N, Kydyralieva R, Sarybaev A. System for the provision of specialised medical care for Covid-19 with comorbid diseases. J Osh State Univ Med. 2025;4(2):8–23. doi:10.52754/16948645_2025_4(2)_08